Abiopharma

Amarin Corporation Plc (AMRN) Reports Q3 2022 Financial Results Amarin Corporation Plc (AMRN) announced its financial results for the period ending Q3 2022. Key Financial Highlights:

• Revenue: 94440
• Net Income: $7
• EPS: (35,643
• Cash and equivalents: 228001
  • targeting the top prescribers and continue to focus on secondary prevention. This business continues to support investments in Europe and expansion into new markets. Amarin continues to actively monitor key performance indicators in the U.S. market to support its strategy moving forward. In the U.S., the company continues to focus on positive contribution margin to support the growth and expansion of VASCEPA/VAZKEPA globally. International Amarin continues to gain traction with its goal to unlock the potential of VASCEPA internationally. The company is in the process of filing regulatory submissions for approval of VASCEPA in 20 additional countries to ensure that patients in the top 50 cardiometabolic markets worldwide can benefit from VASCEPA. In addition, Amarin continues to make meaningful progress in these efforts with our partners. •Amarin received acceptances of the regulatory reviews of VASCEPA market authorization submissions in Australia and New Zealand, with the filings advancing as per local protocols. •In Canada, HLS Therapeutics, Inc. completed negotiations with Canada’s pan-Canadian Pharmaceutical Alliance (pCPA) for the terms and conditions under which VASCEPA would qualify for public market reimbursement in Canada and has received approval from the provinces of Quebec, Ontario, New Brunswick and Northwest Territories, Saskatchewan, as well as the NIHB program for First Nations and Inuit peoples, expanding reimbursement of VASCEPA across the country. •Biologix, Amarin’s partner in the Middle East and North Africa (MENA), received the official registration certificate for VASCEPA from the Kingdom of Saudi Arabia (KSA) regulatory authority for the treatment of severe hypertriglyceridemia. This first approval in KSA enables the preparation and submission of a variation to seek review and approval for the CV risk reduction indication. •Eddingpharm (Asia) Macao Commercial Offshore Limited (Edding), Amarin’s partner in China, received approval for VASCEPA in Hong Kong and is planning for commercial launch by the end of the year. In addition, Edding continues to expect to receive approval for VASCEPA in Mainland China this year. Financial Update Total net revenue for the three months ended June 30, 2022